OCGN Ocugen
- 1.3200
- -0.0700-5.04%
Ocugen News
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Express News | Ocugen Announces Ocu400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and c
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Express News | Ocugen Says It Will Present On Modifier Gene Therapy Platform At Association For Research In Vision And Ophthalmology 2024 Annual Meeting
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Susquehanna
Express News | Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $5
Ocugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 267.65% Chardan Capital $4 → $5 Maintains Buy 04/03/2024 414.71% HC Wainwright & Co. → $7 Reite
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
Ocugen (OCGN) said Friday it has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a modifier gene therapy to treat age-related macular degeneration.
Express News | Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 Armada Clinical Trial of Ocu410—a Modifier Gene Therapy
Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
Ocugen Stock Jumps After $175M Securities Filing
Express News | Ocugen Inc Files for Mixed Shelf of up to $175 Mln - SEC Filing
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors To...
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
Ocugen Says EU Backs a U.S. Trial for Gene Therapy
Express News | Ocugen Disclosed Positive Scientific Advice From The European Medicines Agency Related To The Approval Pathway For Ocu400—Modifier Gene Therapy For Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces Positive Scientific Advice From the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
Analysis
Price Target
No Data
